Our 3PL transition is Complete! Please contact us at GPIcustomerservice@granulespharma.com or 833-879-0063.
We bring you Cost, Quality, Continuity & Compliance
Building on Granules India’s global manufacturing strength, Granules Pharmaceuticals Inc. (GPI) is a 100% US-based subsidiary committed to delivering high-quality, affordable pharmaceutical solutions. Located in Chantilly, Virginia, our US FDA and DEA-approved facility spans over 100,000 square feet and is equipped with established R&D and manufacturing capabilities. GPI specializes in complex, low-volume oral solid dosage forms—including tablets, capsules, powders, and oral solutions—developed and produced in compliance with TAA standards. Offering a one-stop solution for healthcare needs, GPI expands into the over-the-counter segment through its wholly owned LLC, Granules Consumer Health (GCH). Serving as the front-end division for private label OTC products in the US, GCH offers OTC generics and products to our store brand partners that meet the highest level of quality at an affordable cost.
Manufacturing Capabilities At GPI:
- Immediate release tablets & capsules
- Multi-particulate Pellets Modified release dosage forms
- Delayed-release and extended-release tablet and capsule dosage forms
- Orally disintegrating modified release dosage forms
- Chewable modified-release dosage forms
- Microspheres patentable technology platform
- Powders to be reconstituted into Oral Solution (including packaging)
- Modified release suspension
- Private label over the counter (OTC) products
Key Highlights as of the Year Ended March 31st, 2025:
- 34 ANDAs filed from GPI: 31 ANDAs approved and 3 ANDAs under review.
- 43 Products Commercialized by GPI including 17 products filed by Granules India
Limited. - GCH commercialized an additional 20 products under private label.
- Total employee strength in the US : 340+
